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Summary 
Coagulation factor XIII (FXIII) is best known for its role in fibrin stabilization and crosslinking 
of antifibrinolytic proteins to the fibrin clot. From patients with congenital FXIII deficiency it 
was known that FXIII also has important functions in wound healing and maintaning 
pregnancy. Over the last decade more and more research groups with different backgrounds 
have studied FXIII and have unveiled putative novel functions for FXIII. FXIII, with its unique 
role as a transglutaminase among the other serine protease coagulation factors, is now 
recognized as a multifunctional protein involved in regulatory mechanisms and construction 
and repair processes beyond hemostasis with possible implications in many areas of 
medicine. The aim of this review is to give an overview of exciting novel findings and to 
highlight the remarkable diversity of functions attributed to FXIII. Of course, more research 
into the underlying mechanisms and (patho-)physiological relevance of the many described 
functions of FXIII is needed. It will be exciting to observe future developments in this area 
and to see if and how these interesting findings may be translated into clinical practice in the 
future. 
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Introduction 
For a long time, coagulation factor XIII (FXIII) has been known as a neglected coagulation 
factor at the „less interesting“ end of the clotting cascade beyond the diagnostically more 
relevant thrombin generation and fibrin polymerization. FXIII research underwent a revival 
when a role in cardio- and cerebrovascular diseases was first suggested [1-4]. Since then 
more and more research groups with different backgrounds have studied FXIII and thanks to 
their great work over the last decade, FXIII is now recognised as a multifunctional protein 
which is involved in many regulatory and construction and repair processes with possible 
implications in many areas of medicine. In this article we aim to review many exciting new 
functions of a protein belonging to the family of transglutaminases, which exhibit fundamental 
biological reactions in most organisms and are therefore thought to have appeared early in 
the evolutionary history [5].  
Plasma FXIII (pFXIII) is a heterotetramer of two A and two B subunits (FXIII-A2B2). The A 
subunit (FXIII-A) contains the catalytic domain, the B subunit (FXIII-B) serves as carrier and 
regulatory protein. Figure 1 [6] shows the structure of the FXIII-A2 homodimer. In pFXIII, the 
B subunits are thought to be wrapped around FXIII-A2. pFXIII circulates in plasma at an 
average concentration of 21.6 g/ml [8] and is noncovalently bound to fibrinogen. In plasma, 
all FXIII-A exists in complexed form, whereas there are free FXIII-B2 homodimers present. In 
platelets and monocytes/macrophages, cellular FXIII (cFXIII) is present as FXIII-A2. In 
plasma, thrombin initiates the physiological conversion of the zymogen into the active 
enzyme by cleavage of the activation peptide (AP-FXIII), consisting of amino acids 1-37, of 
FXIII-A resulting in FXIII-A2’B2. This reaction is greatly enhanced by polymerized fibrin. The 
dissociation of the A’ and B subunits is induced by conformational changes due to binding of 
Ca2+ and is again enhanced by fibrin. The free thiol group of the active site Cys314 is now 
exposed for the transglutaminase reaction to form a covalent bond between a peptide-bound 
glutamine residue and a peptide-bound lysine residue. Figure 2 schematically shows the 
activation and action of pFXIII [9]. The best known function of pFXIII is clot stabilization 
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during the hemostatic process: FXIII provides a mechanically stronger clot by crosslinking 
fibrin chains [10], and by incorporating antifibrinolytic proteins FXIII prevents the clot from 
premature degradation by the fibrinolytic system [11]. Many other established and emerging 
functions of FXIII and underlying mechanisms are discussed below and summarized in 
Figures 3 and 4. An excellent review article by Muszbek et al. [12] gives a very detailed 
description of FXIII biochemistry and functions. 
 
FXIII deficiency 
Since the description of the first case of congenital FXIII deficiency in 1960 until the 1990s, 
congenital FXIII deficiency was the main area of research on FXIII. With more than 100 
mutations so far described, occuring in all exons of the FXIII-A gene [13], we have learned 
that almost every affected family have their individual mutation. Contrary to hemophilia A, 
mutations in the FXIII-A gene usually lead to complete absence of FXIII-A protein, preventing 
clear genotype-phenotype correlations. However, the very first functional mutation was 
recently discovered at position 37, the thrombin cleavage site, leading to expression of a 
FXIII-A protein that cannot be cleaved by thrombin [14]. Despite of raised awareness and 
availability of specific and sensitive assays, diagnosis of FXIII deficiency is still often 
insufficient and the use of inappropriate assays may lead to missed diagnoses with fatal 
consequences even in developed countries [15]. Diagnosis should therefore follow the 
guidelines of the FXIII and Fibrinogen SSC Subcommittee of the ISTH [16]. Treatment of 
FXIII-A deficiency is undergoing important changes. The first recombinant product has 
proven to be safe and effective and will be available soon [17,18]. Although the old-fashioned 
dogma that 5% of FXIII plasma levels is enough for efficient hemostasis is unfortunately still 
believed by some clinicians, there is increasing evidence that patients with „mild“ FXIII 
deficiency due to congenital heterozygous deficiency, acquired deficiency due to 
consumption, or acquired deficiency due to autoantibodies experience bleeding 
complications in situations such as trauma or surgery [13,19-21]. Data are collected from 
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such cases in ongoing studies with the aim to improve diagnosis, treatment and ultimately 
the outcome in those patients. 
 
FXIII and pregnancy 
Women with congenital FXIII deficiency usually suffer pregnancy loss within the first 
trimester, if not treated with prophylactic FXIII substitution therapy [22,23]. In these patients, 
poor development of the cytotrophoblastic shell and fibrinoid layers, due to impaired protein 
crosslinking, at the interface of maternal and fetal tissue leads to premature detachment of 
the placenta [24]. Therefore, FXIII has an important function in maintaining pregnancy. 
However, it remained unknown whether FXIII plasma levels are altered in FXIII-competent 
women with unexplained recurrent pregnancy loss. In a first study in women with recurrent 
pregnancy loss, low FXIII levels did not predict subsequent miscarriages [25]. This study, 
however, did not compare absolute FXIII levels between patients with and without 
subsequent miscarriage, nor were FXIII levels compared to a control group of women without 
history of recurrent miscarriage. We therefore measured FXIII-A and FXIII-B levels in women 
with two or more unexplained consecutive miscarriages and women without history of 
miscarriage and at least one successful pregnancy [26]. Since FXIII levels did not differ 
between these groups, we conclude that recurrent pregnancy loss in the general population 
is not associated with reduced FXIII plasma levels. Whether locally reduced FXIII-A levels or 
impaired FXIII function in the placenta may contribute to an increased risk of abortion, 
remains to be investigated.  
 
FXIII in wound healing, angiogenesis and atherosclerosis  
Role of FXIII in wound healing after myocardial infarction and atherosclerosis 
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An interesting observation was made about the role of FXIII in myocardial wound healing 
after myocardial infarction (MI). In a murine model of MI, transglutaminase activity during 
acute infarction predicted healing outcome and left ventricular remodelling [27]. FXIII 
treatment induced a faster resolution of the neutrophil response, enhanced macrophage 
recruitment, increased collagen content and augmented angiogenesis in the healing infarct. 
The study also showed decreased FXIII tissue levels in patients with insufficient healing after 
MI. A small clinical study by the same authors confirmed their experimental study: in three 
consecutive patients presenting with acute myocardial rupture following MI, FXIII levels were 
consistently reduced to 50% [28]. To determine whether a truly causative relationship existed 
between FXIII activity and myocardial healing, myocardial repair after left coronary artery 
ligation was studied in FXIII-deficient mice. The results showed that mice lacking FXIII 
suffered from impaired wound healing and fatal rupture of the left ventricle after MI [29]. 
Transglutaminases in general play an important role in cardiovascular disease by numerous 
ways [30]. FXIII may act as signal transduction protein and maintains endothelial barrier 
function by modifying paracellular transport in endothelial cell monolayers [31]. Therefore 
FXIII administration may prevent capillary leakage syndrome in certain clinical scenarios [32].  
Direct evidence for a role for FXIII in atherosclerosis comes from findings that activated FXIII 
(FXIIIa) crosslinks angiotensin-1 (AT1) receptor dimers of monocytes at the onset of 
atherosclerosis. Expression of a FXIIIa-inhibiting peptide reduced AT1-stimulated monocyte 
activation and monocyte entry into the artery wall and inhibited the development of 
atherosclerosis in hypercholesterolemic Apo E−/− mice [33]. In general, atherosclerosis is a 
disease in which inflammation plays a significant role and the modulation of inflammatory 
processes by transglutaminases may be a new approach to further investigate the role of 
FXIII and other transglutaminases in cardiovascular disease. 
 
Proangiogenic properties of FXIII  
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Proangiogenic properties of FXIII have been discovered recently showing another until then 
unknown specific role of this unique coagulation factor. FXIII exerts a direct proangiogenic 
effect on endothelial cells in vitro and promotes angiogenesis in several in vivo animal 
models. Dardik et al. showed for the first time that FXIIIa increased endothelial cell migration 
and proliferation and inhibited apoptosis [34]. The observed proangiogenic effects of FXIII 
were dependent on its transglutaminase activity since the proangiogenic capacity of FXIIIa 
was completely abolished by blockade of its active site. The proangiogenic effect of FXIIIa on 
endothelial cells was accompanied by downregulation of the anti-angiogenic factor 
thrombospondin-1 (TSP-1) [34,35]. TSP-1, an extracellular matrix protein, acts as a 
modulator of various cell processes such as migration, adhesion, proliferation, but also 
apoptosis [36]. In a rabbit cornea model, FXIIIa enhanced neovascularization which was 
associated with an almost complete loss of TSP-1 [34]. 
Substantial in vivo evidence for the proangiogenic activity of FXIII was given by two murine 
models [37]: In a neonatal cardiac allograft transplant model, the number of new vessels was 
higher in FXIII-injected animals than in controls. In a Matrigel plug model, FXIII-deficient mice 
showed lower number of new vessels compared with control mice. Furthermore the number 
of vessels almost reached normal levels following administration of FXIII. Using a different 
animal model Kilian et al. [38] confirmed that FXIII stimulated neovascularization in bone 
defects filled with hydroxyapatite paste. 
The molecular mechanisms underlying the proangiogenic effects of FXIII are complex. 
Binding of FXIII-A to endothelial cells requires integrins [39] and FXIIIa induces up-regulation 
of several transcription factors affecting cell proliferation and differentiation, vasculogenesis 
and angiogenesis [40].  Dardik et al. [41] showed that the proangiogenic effect of FXIIIa is 
mediated by 1) enhancement of crosslinked and noncovalent αvβ3/VEGFR-2 complex 
formation (αvβ3: integrins involved in angiogenesis and vasculogenesis; VEGFR-2: vascular 
endothelial growth factor receptor 2);  2) tyrosine phosphorylation and activation of VEGFR-
2; 3) upregulation of transcription factors  c-Jun and Egr-1; and 4) downregulation of TSP-1 
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induced indirectly by c-Jun through WT-1 (Wilm’s tumor-1). These findings shed light on the 
mechanisms by which FXIII is involved in angiogenesis and tissue repair. 
 
The role of FXIII in bone metabolism and bone disease 
Transglutaminases, bone metabolism and extracellular matrix stabilization 
Bone represents a dynamic tissue that is under constant remodelling throughout life [42]. The 
two major cells involved in these processes are osteoclasts that resorb bone and osteoblasts 
that form new bone tissue. Extracellular matrix (ECM) represents the biological substratum 
that supports these cells by fascilitating cell attachment, cell differentation, but also regulates 
bone mineralization. Secretion and assembly of bone ECM is conducted by osteoblasts and 
is regulated by cytokines, hormones and by their ionic microenvironment and the ECM itself. 
Stimulation of osteoblasts leads to ECM production and finally matrix mineralization [43].  
Fully differentiated osteoblasts deposit bone matrix of which approximately 90% is collagen 
type-1. The remaining part is composed of proteoglycans and various proteins. Disturbed 
osteoblast activity contributes to defective bone deposition. 
Transglutaminases are well known to be involved in ECM stabilization in different tissues. 
From the transglutaminase family only transglutaminase 2 (TG2)  and FXIII are involved in 
cartilage and endochondral ossification [44-46]. It is interesting to note that TG2-knockout 
mice have no overt skeletal phenotype, suggesting that besides TG2 another 
transglutaminase with at least partially overlapping functions must be involved [47]. Nakano 
et al. confirmed by immunohistochemistry, in situ hybridization, and biochemical methods 
that FXIII-A was expressed in vivo by osteoblasts and osteocytes in bones formed by both 
intramembranous and endochondral ossification [48]. FXIII-A was present in bone tissue and 
in osteoblast cultures mostly as a small 37-kDa form, presumably resulting from 
posttranslational proteolytic processing of the parent enzyme. This 37-kDa form of FXIII-A 
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was found to be associated with the osteoblast plasma membrane as part of the osteoblast 
differentiation process. 
Al-Jallad et al. presented new functions of FXIII in osteoblast matrix secretion and deposition 
[49]. They showed that FXIII-A and its crosslinking activity were colocalized with plasma 
membrane-associated tubulin. Thus FXIII-A crosslinking activity appeared to be directed 
towards stabilizing the interaction of microtubules with the plasma membrane. These results 
provide strong evidence how transglutaminase activity could affect protein secretion and 
matrix deposition in osteoblasts and suggest a novel function for plasma membrane FXIII-A 
in microtubule dynamics. How FXIII-A activation occurs remains elusive; possible candidates 
include membrane-bound proteases matrix metalloproteinase-2 (MMP-2) and PHEX 
(phosphate-regulating gene with homology to endopeptidases on the X-chromosome) [50]. 
Newer results from the same group [51] showed that osteoblasts secreted a latent, inactive 
dimeric ECM form of FXIII-A (ecmFXIII-A) which was activated upon binding to the matrix by 
a so far unknown mechanism. Cross-linking activity was detected at sites where fibronectin 
colocalized with collagen type-1, indicating that ecmFXIII-A secretion could function to 
stabilize newly deposited matrix. Thus, FXIII-A may be an integral part of the collagen type-1 
deposition machinery and of the ECM-feedback loop, both of which regulate matrix 
deposition and osteoblast differentiation. 
In summary, these data show another important function of FXIII besides its role in 
coagulation. In bone metabolism, FXIII seems to play a synergistic role to TG2 in ECM 
deposition and osteoblast differentiation. 
 
The role of FXIII in bone disease 
Osteoarthritis is a common cause of disability in the elderly that is characterized by cartilage 
degradation, synovium and tendon inflammation, osteophyte formation accompanied by 
subchondral bone remodeling by osteoid substance accumulation, and decreased 
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mineralization. Sanchez et al. [52] investigated gene expression in human osteoblasts 
isolated from sclerotic or nonsclerotic areas of subchondral bone. FXIII-A expression was 
significantly up-regulated in sclerotic osteoblasts compared with nonsclerotic osteoblasts 
confirming a role of FXIII in bone remodelling [52]. 
 
Significance of FXIII antigen levels in severe trauma and surgery 
Hemorrhagic shock represents a dangerous complication of severe trauma and is associated 
with high mortality and morbidity due to inadequate capillary perfusion in vital organs and 
tissues. The condition is called trauma-hemorrhagic shock (THS) which leads to a reduction 
of circulatory blood volume. This results in insufficient organ microcirculation, tissue hypoxia 
and finally organ damage. Most THS patients develop severe coagulopathy due to loss of 
coagulation and fibrinolytic proteins by bleeding and/or consumption [53,54]. Loss of these 
proteins cause prolongation of routine coagulation tests such as activated partial 
thromboplastin time (APTT) and prothrombin time (PT). Thrombelastography (TEG) and 
rotation thrombelastometry (ROTEM) are ideal bedside tests to provide fast and reliably 
information on the existance or development of coagulopathies [55-57]. Immediate 
identification of patients at risk is of critical importance in order to goal-direct transfusion 
therapy with specific coagulation proteins, platelets and/or antifibrinolytic agents. 
FXIII has a significant impact on thrombelastographic parameters suggesting a major role of 
FXIII in patients with these conditions [58]. However, its benefit in trauma as well as surgical 
patients is still under debate, especially the question what level of FXIII antigen is required to 
maintain hemostasis. Clinical studies in surgical patients suggested an increased bleeding 
tendency at FXIII activity levels below 60%  [59-62]. 
Still, there is insufficient evidence to judge the extent of blood loss or acute coagulopathy that 
lead to a critical decrease in FXIII antigen levels which could be potentially dangerous during 
and after a surgical procedure. However, it is well known that trauma-induced shock and 
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coagulopathy lead to disseminated intravascular coagulation including significant 
consumption of FXIII [63]. A recent animal study investigated the role of FXIII in shock-
induced organ dysfunction: rats were subjected to THS or trauma sham shock and were 
treated with either recombinant cellular FXIII-A2 (rcFXIII) or placebo. Administration of rcFXIII 
diminished THS-induced multiple organ dysfunction, presumably by preservation of the gut 
barrier function, limitation of polymorphonuclear leukocyte activation, and modulation of the 
cytokine response [64].  
 
FXIII as part of the insulin resistance syndrome 
Insulin resistance represents a common metabolic abnormality increasing the risk of type 2 
diabetes mellitus (T2DM) and cardiovascular disease, the major cause of morbidity and 
mortality in most parts of the world. Insulin resistance is not simply a problem of deficient 
glucose uptake in response to insulin but represents a multifaceted syndrome called insulin 
resistance syndrome which is associated with atheromatous risk factor such as dyslipidemia, 
hyperinsulinemia, obesity, and hypertension, affecting around 25% of a Western population 
[65,66]. It became more and more evident that not only the clustering of atheromatous risk 
factors belongs to the syndrome but also atherothrombotic risk factors such as increased 
plasma levels and/or certain genetic variants of fibrinogen, FVII and most notably 
plasminogen activator inhibitor-1 (PAI-1) [67]. In addition there is evidence that also FXIII 
levels cluster with these risk factors contributing to the prothrombotic state which may in turn 
enhance cardiovascular risk. FXIII-A and FXIII-B antigen levels are elevated in patients with 
T2DM and FXIII-A antigen levels are increased in relatives of subjects with T2DM [68]. The 
specific role and the underlying mechanisms of FXIII in this complex syndrome needs further 
investigation. Since inflammation is another feature of the insulin resistance syndrome and 
FXIII is also involved in inflammatory processes as outlined below, these may represent a 
link between FXIII and the insulin resistance syndrome. 
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FXIII and immune defence and inflammation 
The simultaneous activation of coagulation and inflammatory processes after injury is a 
phylogenetically ancient adaptive response that can be traced back to early eukaryotic 
evolution [69]. The aim of co-activation and interactions between coagulation and 
inflammatory processes is to protect the host from blood loss and infection. FXIII plays a role 
in infection control and interacts with complement factors and inflammatory cells [recently 
reviewed by 70]. 
Induction of coagulation leads to immobilization and killing of bacteria inside the clot. This 
entrapment is mediated via crosslinking of bacteria to fibrin fibers by FXIIIa. FXIII knock-out 
mice developed severe signs of inflammation at the site of infection, whereas FXIII treatment 
of wild-type animals reduced bacterial dissemination during early infection [71]. In sepsis, 
FXIII protected mucosal capillary perfusion against endotoxin-induced impairment in a rat 
model [72]. Administration of FXIII also reduced hemorrhagic shock-induced organ 
dysfunction in rats by preserving lung and gut endothelial barrier function and limiting 
leukocyte activation [64]. While activation of FXIII is beneficial in fighting infection and 
improving endothelial barrier function (first shown by Noll et al. [31]), it also has negative 
effects in sepsis by increasing the risk of intravascular thrombosis, as depletion of FXIII was 
shown to prevent disseminated intravascular coagulation-induced organ damage in rabbits 
[73]. 
The complement system is an important part of innate immunity and FXIII interacts with 
proteins of the complement system. Its central component complement C3 is incorporated 
into fibrin clots and prolongs fibrinolysis [74,75]. Incorporation occurs by noncovalent binding 
to fibrinogen/fibrin and covalent crosslinking by FXIIIa. Thus, complement C3 is a novel 
substrate for FXIIIa [76,77]. Mannan-binding lectin-associated serine protease-1 (MASP-1) of 
the complement lectin pathway has a similar substrate specificity to thrombin, and we and 
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others have shown that MASP-1 also activates FXIII [78]. These interactions may contribute 
to the prothrombotic state accompanying many inflammatory diseases. 
FXIII also interacts with cells of the immune system (recently reviewed by Bagoly et al. [79]. 
Interactions include activation of FXIII by human neutrophil elastase, downregulation of 
FXIIIa within the clot by granulocyte proteases, and enhancing effects of FXIII on monocyte 
proliferation and migration and inhibition of monocyte apoptosis [79]. 
Monocytes/macrophages have been discussed as a source of FXIII-A in plasma, and despite 
of some evidence for a non-classical secretion pathway of cFXIII from these cells [79,80] the 
origin of plasma FXIII-A is not yet proven. An association between FXIIIVal34Leu 
polymorphism and monocyte and neutrophil cell counts following LPS infusion in humans 
has been suggested [81], however, due to the small sample size in this study larger studies 
are needed to confirm this finding and investigate possible underlying mechanisms. 
Inflammatory bowel diseases (IBD) have long been associated with decreased FXIII levels. A 
recent study in Crohn’s disease has shown, however, that FXIII levels can not be 
recommended as a marker for disease activity [82]. The mechanisms leading to decreased 
FXIII levels in IBD are controversially discussed. While one study suggested FXIII 
consumption due to coagulation activation based on findings of elevated D-dimer and 
prothrombin fragment 1+2 in patients with active ulcerative colitis or Crohn’s disease [83], 
another study did not find increased thrombin-antithrombin complex levels in patients with 
active Crohn’s disease and suggested that FXIII was not consumed due to coagulation 
activation but due to repair of injured tissue [84]. This was supported by a histological study 
which detected tissue transglutaminase and FXIII-A in damaged areas of the colon 
underpinning the important role of transglutaminases in mucosal healing [85]. However, it is 
not yet clear whether patients with IBD benefit from administration of pFXIII as clinical 
studies have yielded contradictory results [86,87]. Severe graft-versus-host disease (GvHD) 
of the gut is a relatively frequent complication of haematopoietic stem cell transplantation and 
manifests with similar symptoms as IBD. There is also a significant decrease in FXIII plasma 
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levels in patients with GvHD [88] and these patients may benefit from FXIII replacement 
therapy [89]. 
 
FXIII in neoplasm 
In regard to neoplasm FXIII has come to attention 1) as a marker for certain types of 
leukemia and carcinoma and 2) with decreased plasma levels due to coagulation activation 
and consumption. 
The cellular form of FXIII (FXIII-A2) is present in platelets, megakaryocytes, monocytes and 
macrophages and thus has been detected in mono- and megakaryocytic leukemias [90]. In 
patients with acute myeloblastic leukemia (AML) M4 and M5, FXIII-A was a sensitive marker 
for blast cells [90,91] in which expression levels were markedly increased compared to 
normal cells. Recently, FXIII-A has also been detected as a marker in acute promyelocytic 
leukemia (APL) M3 [92]. Surprisingly, FXIII-A expression was found in 19 out of 47 cases of 
newly diagnosed B cell acute lymphoblastic leukemia (ALL) [93]. Expression of FXIII-A can 
be considered as leukemia-associated immunophenotype which may be of value for 
diagnosis and disease monitoring [90,92]. 
Leukemia is also associated with consumption of pFXIII. In a child presented in a case 
report, FXIII plasma levels of only 56% and increased D-dimer levels preceded diagnosis of 
ALL by 6 weeks and FXIII levels normalized when the child was in remission [94]. In a young 
woman, retro-bulbar hematoma associated with FXIII-A antigen levels as low as 7.6% 
preceded diagnosis of APL by 2.5 weeks [95]. 
FXIII has also been studied in regard to solid tumors. FXIII is related to certain types of 
neoplasms of the skin. In normal skin, FXIII-A is expressed in specific dermal dendrocytes 
(DD) derived from the monocyte/macrophage lineage or from mesenchymal origin [96]. In 
tumor pathology, expression of FXIII-A is used e.g. to distinguish between dermatofibroma 
and dermatofibrosarcoma protuberans [97,98]. In addition, FXIII-A+ DD are found in 
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fibrovascular lesions including fibrous papules of the nose, acquired digital fibrokeratomas, 
angiofibromas, oral fibromas [99] or desmoplastic neoplasms where FXIII-A is possibly acting 
as a growth factor. FXIII-A+ DD may also be involved in the progression and regression of 
some malignancies including cutaneous melanoma and basal cell carcinoma [96]. A study in 
130 patients with oral squamous cell carcinoma and 135 healthy controls suggested that the 
Leu allele of the FXIIIVal34Leu polymorphism was associated with increased risk for this 
type of cancer. As a possible mechanism it was poposed that a less porous fibrin network 
composed of thinner fibers may facilitate tumor stroma formation and tumor cell proliferation 
[100]. In 110 patients with breast cancer, significantly lower expression levels of FXIII were 
found in tumor tissues compared with normal mammary tissues (n=27) [101]. 
FXIII may also play a role in metastasis. Wild-type and FXIII-deficient mice were injected with 
Lewis lung carcinoma and B16–BL6 melanoma cells. Metastatic potential was significantly 
diminished in FXIII-A deficient mice relative to control animals. FXIII was shown to support 
metastasis primarily by limiting natural killer cell-mediated clearance of micrometastatic 
tumor cells [102]. Human data, however, are lacking so far. 
 
Novel functions of FXIII 
FXIII in tears 
FXIII-A and FXIII-B subunits and FXIII tetramer have been detected in human tears at low 
concentration [103,104]. The source of FXIII in tears remains unknown, but possible sources 
include leakage from plasma or production in conjunctival macrophages or corneal epithelial 
cells. Since most of FXIII in tears exists as FXIII-A2, non-proteolytic activation in presence of 
Ca2+ is likely to occur. Alternatively, proteolytic cleavage by thrombin that has leaked from 
plasma or by granulocyte elastase is possible. In patients undergoing corneal 
transplantation, FXIII concentrations (normalised for protein concentration) increased up to 
25 fold on the first postoperative day, followed by a gradual decrease over the next seven 
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days. Patients who later developed the complication of neovascularisation of the donor 
cornea showed the highest FXIII levels. It was suggested that FXIII in tears may be involved 
in corneal wound healing, whereas high FXIII levels may represent a risk factor for 
neovascularisation by promoting angiogenesis [104].   
 
Optic nerve regeneration 
A novel function for cellular FXIII-A in neuronal regeneration has been proposed in fish [105]. 
In fish, unlike in mammals, neurons of the central nervous system are capable of self-repair 
and regeneration, and research goes on to identifiy factors inducing/involved in repair 
processes. Upon optic nerve injury in goldfish, in situ FXIII activity increased accompanied by 
expression of FXIII-A mRNA. The cells producing FXIII-A were identified as 
astrocytes/microglial cells in the optic nerve. In retinal cell culture, overexpression of FXIII-A 
promoted neurite sprouting and elongation [105]. Further studies are needed to elucidate the 
underlying mechanisms. Whether this may have future implications in human medicine is so 
far unknown. 
 
Liver remodeling 
In a murine model of acute liver injury, FXIII-A deficiency led to increased hepatocyte 
apoptosis and delay in hepatocyte regeneration. It was concluded that the effects of FXIIIa 
on ECM protein crosslinking and matrix formation could promote survival of hepatocytes in 
liver remodeling [106]. 
 
FXIII-B subunit is not only a carrier for the FXIII-A subunit 
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The gene encoding FXIII-B is located on chromosome 1 and belongs to the regulator of 
complement activation (RCA) gene cluster [107]. FXIII-B with its 10 short consensus repeats, 
also called Sushi domains, resembles other binding and regulatory proteins such as 
complement factor H or C4b-binding protein. Furthermore, FXIII-B plasma concentration is 
twice as high as FXIII-A concentration, i.e. 50% of FXIII-B is free and in excess over FXIII-A. 
Therefore it would be plausible if the FXIII-B subunit had other functions in addition to its 
carrier function for FXIII-A. One novel function has been recently described by the group of L. 
Muszbek [108]. They have shown that FXIII-B binds Staphylococcus aureus protein A (SpA) 
with high affinity. SpA on the bacterial surface binds human IgG in incorrect orientation 
preventing recognition and phagocytosis by macrophages. FXIII-B saturates SpA and inhibits 
incorrect binding of IgG and may thus promote opsonization and subsequent phagocytosis of 
the bacteria. This may represent a novel role for FXIII-B in immune defence. 
 
AP-FXIII as marker of thrombosis and regulator of coagulation 
It has long been known that thrombin initiates the physiological conversion of FXIII-A2B2 
zymogen into the active enzyme by cleavage of the N-terminal activation peptide (AP-FXIII). 
Until recently, however, it was unclear whether the AP-FXIII is indeed released into plasma 
under physiological conditions. Neither had it been explored whether free AP-FXIII, in case it 
was indeed released into circulation, might have any physiological functions. 
We therefore developed an ELISA method with two sensitive and specific monoclonal 
antibodies against free AP-FXIII and we showed that AP-FXIII is released into plasma upon 
FXIII activation [6,109]. We then performed a pilot study to provide proof-of-principle, that in 
vivo generated AP-FXIII can be detected in patients with an acute thrombotic event [110]: we 
investigated FXIII activation in the early phase of acute ischaemic stroke by repeated 
measurements of free AP-FXIII, FXIII-A and FXIII-B subunit antigen levels in plasma 
samples from patients within 48 hours of acute ischaemic stroke. Free AP-FXIII could be 
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detected in 34 out of 66 patients upon hospital admission (range 0.2-26.3 ng/ml), on day 1 in 
15 patients (0.2-10.4 ng/ml), and on day 2 in 11 patients (0.1-15.1 ng/ml). AP-FXIII was 
higher in patients with severe stroke. Lower AP-FXIII levels upon admission were associated 
with clinical improvement. Larger studies are needed to assess whether AP-FXIII might serve 
as a diagnostic and/or prognostic marker for acute thrombotic diseases. 
We are currently investigating whether free AP-FXIII may affect FXIII function and fibrin 
formation and structure. Preliminary results show that free AP-FXIII, but not a scrambled 
peptide of the same amino acid composition but in random order, reduces thrombin-induced 
FXIII activation and affects fibrin clot structure, suggesting that free AP-FXIII may interact 
with thrombin and compete with the thrombin substrates FXIII and fibrinogen [111; and 
unpublished own data]. Whether free AP-FXIII may act as a negative feedback regulator of 
thrombin-induced clot formation remains to be confirmed. 
 
Concluding remarks 
The aim of this review was to highlight the remarkable diversity of functions attributed to 
FXIII. This diversity may partly originate from its enzymatic characteristics as a 
transglutaminase, since transglutaminase reactions represent important posttranslational 
modifications by covalently crosslinking proteins which can change their properties and 
biological effects. This makes FXIII uniques among the hemostatic proteins which are mainly 
protein-cleaving serine proteases. Indeed, there is increasing evidence that FXIII actually has 
more functions beyond than within hemostasis. Therefore and as the only transglutaminase 
circulating in plasma, the name „plasma transglutaminase“ may be more appropriate than 
„coagulation FXIII“.  
Having discussed FXIII as a protein with so many important functions in different processes 
beyond hemostasis, it may seem at odds that FXIII deficiency does exist and hence is 
compatible with life. One conclusion may be that FXIII has a rather modulating than exclusive 
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role and that FXIII and other transglutaminases may have evolved as redundant systems 
supporting each other in fulfilling certain tasks. The specific contributions and interrelations of 
the different transglutaminases especially on cellular level are still not well known. In regard 
to its function in blood coagulation, however, there is no physiological replacement or 
compensation for FXIII, and the severity of congenital FXIII deficiency is highlighted by two 
facts: 1) Without medical treatment, most of the affected individuals die at young age. An 
extensive Swiss family pedigree going back to the 17th century [9,112] illustrated the 
devastating effect FXIII deficiency had on that family over the years. 2) Normal pregnancy is 
unlikely in affected women which possibly makes FXIII deficiency more difficult to pass on 
than other hereditary diseases. 
Clearly, more research into the underlying mechanisms and (patho-) physiological relevance 
of the many described functions of FXIII is needed. It will be exciting to observe future 
developments in this area and to see if and how these interesting findings may be translated 
into clinical practice in the future. 
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Figure legends 
Figure 1. Structure of the FXIII A2 homodimer. (Reproduced from [6] with permission). 
One monomer is shown in ribbons with the activation peptide colored in pink and the N-
terminus indicated as a ball. The -sandwich domain is colored in blue, the catalytic core 
domain in green, and the barrel 1 and barrel 2 domains in orange and red, respectively. The 
other monomer is represented as surface. The coordinates from the protein data base (PDB) 
originate from the crystal structure [7]. 
Figure 2. Activation and action of plasma FXIII. Thrombin initiates FXIII activation by 
cleavage of the FXIII activation peptide. Then A- and B-subunits dissociate in the presence 
of Ca2+. Both FXIII activation steps are enhanced by fibrinogen/fibrin. Thrombin also initiates 
conversion of fibrinogen into soluble fibrin by cleaving off fibrinopeptides A and B. Activated 
FXIII (FXIIIa) crosslinks lysine (Lys) and glutamine (Gln) residues of fibrin - and γ-chains in 
a transglutaminase reaction leading to a three-dimensional, insoluble fibrin network. 
Figure 3. Diversity of FXIII functions. As a result of its multiple functions, FXIII is involved 
in many different physiological and pathophysiological processes and hence FXIII is of 
interest in different areas of biology and medicine. 
Figure 4. Mechanisms and substrates of FXIII. As a transglutaminase, activated FXIII 
crosslinks many different proteins of the coagulation cascade, extracellular matrix, 
complement system and intracellular proteins. FXIII also interacts – directly or indirectly – 
with various cell types. (TAFI: thrombin-activatable fibrinolysis inhibitor; PAI-2: plasminogen-
activator inhibitor-2; ECM: extracellular matrix; VEGFR: vascular endothelial growth factor 
receptor; TSP-1: thrombospondin-1; AT1: angiotensin-1; PMN: polymorphonuclear; MASP-1: 
mannan-binding lectin-associated serine protease-1.) 
 
 
28 
 
Figure 1 
 
 
 
 
 
 
 
 
 
29 
 
Figure 2 
 
30 
 
Figure 3 
 
31 
 
Figure 4 
 
 
 
